NAVICAN PRECISION CANCER CARE - Trademark Details
Status: 700 - Registered
Image for trademark with serial number 87978077
Serial Number
87978077
Registration Number
5771247
Word Mark
NAVICAN PRECISION CANCER CARE
Status
700 - Registered
Status Date
2019-06-04
Filing Date
2017-05-30
Registration Number
5771247
Registration Date
2019-06-04
Mark Drawing
4000 - Standard character mark Typeset
Published for Opposition Date
2017-11-07
Attorney Name
Law Office Assigned Location Code
M80
Employee Name
LEASER, ANDREW C
Statements
Disclaimer with Predetermined Text
"PRECISION CANCER CARE"
Goods and Services
Pharmaceutical benefit management services; insurance claims processing in the field of diagnostics and pharmaceutical claims; providing a database featuring information and statistics about patient reimbursement and insurance coverage for diagnostics and pharmaceuticals; reimbursement payment processing in the field of diagnostics and pharmaceutical claims; providing information in the field of financial support options and resources for prescribers, patients and the pharmaceutical industry; providing patient reimbursement and insurance coverage information in the field of drug reimbursement for prescribers, patients and the pharmaceutical industry; providing patient reimbursement and insurance coverage information in the field of diagnostics reimbursement for providers and patients; and financial administration of diagnostics and pharmacy reimbursement programs and services
Goods and Services
Medical, clinical and scientific research in the field of oncology, namely, research relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; scientific and technological services, namely, research services for medical purposes in the field of genetic diagnostic assays and pharmaceuticals research for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information and scientific consulting in the field of genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; conducting early evaluations in the field of new genetic diagnostics assays and pharmaceuticals; development, evaluation and medical and scientific research of genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; laboratory research services relating to genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals, clinical trials and genetics; technical consulting related to scientific and medical studies in the field of genetic diagnostic assay and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; basic and clinical research in the field of oncology, namely, researching genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals and clinical trials for personalized diagnosis, treatment and prevention of cancer; custom design and development of chemical reagants and multiplex sequencing assays for personalized diagnosis, treatment and prevention of cancer; providing an on-line computer database featuring medical and scientific research information in the field of oncology that allows for input and collection of scientific and research data and information relating to genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, data mining and pattern recognition, designing clinical studies, and generating genomic data from patient samples for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection and systematic sorting of clinical and patient data comprising patient specific clinical data and scientific clinical studies relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection of mathematical and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to cancer treatments for personalized diagnosis, treatment and prevention of cancer; compiling data for research purposes in the field of medical science, namely, compiling patient specific molecular and genomic data, patient specific clinical data and scientific clinical studies for personalized diagnosis, treatment and prevention of cancer; providing a website featuring technology with a web-based interface where medical professionals can view genetic test results and interpretations of the results by scientists and medical professionals in the field of genomics, and select the appropriate treatment and order the necessary pharmaceutical products
Classification Information
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2017-06-06
Primary Code
042
First Use Anywhere Date
2018-04-23
First Use In Commerce Date
2018-04-23
Current Trademark Owners
Party Type
31 - 1st New Owner Entered After Registration
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Type
31 - 1st New Owner Entered After Registration
Address
Please log in with your Justia account to see this address.
Party Type
30 - Original Registrant
Address
Please log in with your Justia account to see this address.
Party Type
20 - Owner at Publication
Address
Please log in with your Justia account to see this address.
Party Type
10 - Original Applicant
Address
Please log in with your Justia account to see this address.
Correspondences
Name
JOSHUA G. GIGGER
Address
Please log in with your Justia account to see this address.
Prior Registrations
Relationship TypeReel Number
Continuity Parent87468478
Madrid International Filings
Entry Number
1
Reference Number
A0071255
Original Filing Date USPTO
2017-11-07
International Registration Number
1389030
International Registration Date
2017-11-07
International Status Code
480
International Renewal Date
2027-11-07
Madrid History Events
DateCodeDescription
2019-10-17CHGOWCHANGE OF OWNER RECEIVED FROM IB
2019-10-17CHGOWCHANGE OF OWNER RECEIVED FROM IB
2017-11-07NEWAPNEW APPLICATION FOR IR RECEIVED
2017-11-08MCERTMANUALLY CERTIFIED
2017-11-08APPSTIR CERTIFIED AND SENT TO IB
2017-12-05IRREGIRREGULARITY NOTICE RECEIVED FROM IB
2018-01-02IRRCVIRREGULARITY RESPONSE RECEIVED FROM APPLICANT
2018-01-12IRRACRESPONSE TO IRREGULARITY REVIEWED AND ACCEPTED
2018-01-12IRSNTIRREGULARITY RESPONSE SENT TO IB
2018-02-15CREATAPPLICATION FOR IR REGISTERED BY IB
2019-08-07CBMPPCEASING OF EFFECT PROCESSED
2018-04-23CBPCPPARTIAL CEASING OF EFFECT TO BE PROCESSED
2019-08-07CBPSPPARTIAL CEASING OF EFFECT NOTICE SENT TO IB
2018-04-26CBNARCEASING OF EFFECT REVIEWED - NO ACTION REQUIRED BY OFFICE
2018-08-24PDBNXDIVISION OF BASE APPLICATION PROCESSED BY IB
2019-08-05CBPCPPARTIAL CEASING OF EFFECT TO BE PROCESSED
2019-09-18CBNARCEASING OF EFFECT REVIEWED - NO ACTION REQUIRED BY OFFICE
2018-07-16DBCSPDIVISIONAL OF BASE APP NOTICE SENT TO IB
2018-07-14DBCRPDIVISIONAL OF BASE APP NOTICE CREATED, TO BE SENT TO IB
2019-09-04CBPCPPARTIAL CEASING OF EFFECT TO BE PROCESSED
2019-10-04PCBNPPARTIAL CEASING OF EFFECT PROCESSED BY IB
Trademark Events
Event DateEvent Description
2017-06-02NEW APPLICATION ENTERED IN TRAM
2017-06-06NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2017-08-17ASSIGNED TO EXAMINER
2017-08-24EXAMINERS AMENDMENT -WRITTEN
2017-08-24EXAMINERS AMENDMENT E-MAILED
2017-08-24NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
2017-08-24EXAMINER'S AMENDMENT ENTERED
2017-08-26EXAMINERS AMENDMENT -WRITTEN
2017-08-26EXAMINERS AMENDMENT E-MAILED
2017-08-26NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
2017-08-26EXAMINER'S AMENDMENT ENTERED
2017-09-16APPROVED FOR PUB - PRINCIPAL REGISTER
2017-10-01ASSIGNED TO LIE
2017-10-18NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2017-11-07PUBLISHED FOR OPPOSITION
2017-11-07OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2018-01-02NOA E-MAILED - SOU REQUIRED FROM APPLICANT
2018-06-29TEAS STATEMENT OF USE RECEIVED
2018-06-29TEAS REQUEST TO DIVIDE RECEIVED
2018-07-13CASE ASSIGNED TO INTENT TO USE PARALEGAL
2018-06-29DIVISIONAL REQUEST RECEIVED
2018-07-13DIVISIONAL PROCESSING COMPLETE
2018-06-29USE AMENDMENT FILED
2018-07-13STATEMENT OF USE PROCESSING COMPLETE
2018-08-02SU - NON-FINAL ACTION - WRITTEN
2018-08-02NON-FINAL ACTION E-MAILED
2018-08-02NOTIFICATION OF NON-FINAL ACTION E-MAILED
2018-09-13TEAS RESPONSE TO OFFICE ACTION RECEIVED
2018-09-13CORRESPONDENCE RECEIVED IN LAW OFFICE
2018-09-14TEAS/EMAIL CORRESPONDENCE ENTERED
2018-10-04SU - FINAL REFUSAL - WRITTEN
2018-10-04FINAL REFUSAL E-MAILED
2018-10-04NOTIFICATION OF FINAL REFUSAL EMAILED
2019-05-02SU-EXAMINER'S AMENDMENT WRITTEN
2019-05-02EXAMINERS AMENDMENT E-MAILED
2019-05-02NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
2019-05-02EXAMINER'S AMENDMENT ENTERED
2019-05-02ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
2019-05-03NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
2019-06-04REGISTERED-PRINCIPAL REGISTER
2019-08-14AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP